PULMONX CORPORATION Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
PULMONX CORPORATION (LUNG) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $11.91 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-04
- PULMONX CORPORATION share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $9.47, a 43.05% decline year-over-year.
- PULMONX CORPORATION share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $16.63, a 11.87% decline year-over-year.
- PULMONX CORPORATION share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $18.87, a 9.14% increase year-over-year.
- PULMONX CORPORATION share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $17.29, a 25.79% decline year-over-year.
- PULMONX CORPORATION share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $9.05, a 58.79% decline from fiscal 2024.
- PULMONX CORPORATION share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $21.96, a 6.50% increase from fiscal 2023.
- PULMONX CORPORATION share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $20.62, a 27.14% decline from fiscal 2022.
- PULMONX CORPORATION share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $28.30, a 147.38% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.91 10-Q · filed 2026-08-04 | |||
| 2026-03-31 | $9.47 10-Q · filed 2026-05-04 | |||
| 2025-12-31 | $9.05 10-K · filed 2026-03-10 | |||
| 2025-09-30 | $15.70 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $15.70 10-Q · filed 2025-08-01 | |||
| 2025-03-31 | $16.63 10-Q · filed 2025-05-02 | |||
| 2024-12-31 | $21.96 10-K · filed 2026-03-10 | |||
| 2024-09-30 | $21.62 10-Q · filed 2024-11-01 | |||
| 2024-06-30 | $21.85 10-Q · filed 2024-08-02 | |||
| 2024-03-31 | $18.87 10-Q · filed 2024-05-03 | |||
| 2023-12-31 | $20.62 10-K · filed 2025-02-25 | |||
| 2023-09-30 | $21.67 10-Q · filed 2023-11-03 | |||
| 2023-06-30 | $19.60 10-Q · filed 2023-08-04 | |||
| 2023-03-31 | $17.29 10-Q · filed 2023-05-08 | |||
| 2022-12-31 | $28.30 10-K · filed 2024-02-27 | |||
| 2022-09-30 | $28.19 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $19.96 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | $23.30 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $11.44 10-K · filed 2023-03-01 | |||
| 2021-09-30 | $11.26 10-Q · filed 2021-11-09 | |||
| 2021-06-30 | $10.97 10-Q · filed 2021-08-10 | |||
| 2021-03-31 | $2.44 10-Q · filed 2021-05-12 | |||
| 2020-12-31 | $3.55 10-K · filed 2022-03-01 | |||
| 2020-09-30 | $4.67 10-Q · filed 2020-11-13 | |||
| 2019-12-31 | $1.39 10-K · filed 2021-03-15 | |||
| 2018-12-31 | $1.53 10-K · filed 2021-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SkinHealth Systems Inc. (SKIN) | United States | $0.086B | -3.17 |
| LENSAR, Inc. (LNSR) | United States | $0.087B | 2.02 |
| RenovoRx, Inc. (RNXT) | United States | $0.076B | -3.62 |
| Microbot Medical Inc. (MBOT) | $0.089B | -7.97 | |
| FRACTYL HEALTH, INC. (GUTS) | United States | $0.075B | -1.18 |
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 | |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| Spectral AI, Inc. (MDAI) | United States | $0.052B |